Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Progerinin for Bone Mineral Density Loss in Werner Syndrome
NCT05847179Phase 2Recruiting
- Sponsor
- PRG Science & Technology
- Start
- Oct 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Progerinin in Werner syndrome (WS), sponsored by PRG Science & Technology. Primary endpoints: Incidence and severity of Treatment-Emergent Adverse Events at Week 56 and Incidence of Serious Adverse Events at Week 56. Started Oct 2026; status: recruiting.
02
Drugs
Progerinin
03
Conditions
Werner syndrome (WS)
Beyond the preview
Go deeper on NCT05847179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05847179.